Pfizer - zu Unrecht im Keller
Seite 108 von 197 Neuester Beitrag: 18.04.24 18:47 | ||||
Eröffnet am: | 21.10.04 12:39 | von: Anti Lemmin. | Anzahl Beiträge: | 5.909 |
Neuester Beitrag: | 18.04.24 18:47 | von: tiffany123 | Leser gesamt: | 1.205.282 |
Forum: | Börse | Leser heute: | 880 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 106 | 107 | | 109 | 110 | ... 197 > |
sehe eher eine Phase der Konsildierung, überhitzt sieht wirklich etwas anders aus. Aber auch ein Bluechip kann und mann mal seitwärts tendieren nach Anstiegen. Dazu kommt das noch positive relevanten Nachrichten + Dividende anstehen...
@Bertel
Verstehe nicht was da verhagelt werden soll, meine Sichtweise ist das man die gewinnbringende Zusammenarbeit intensivieren wird und das man Wettbewerbern klar zeigt das man hier stark positioniert ist. Covid 19 ist ja nur ein Thema von vielen die man mit BioNtec angehen wird.
Mir macht eine Aussage von AstraZeneca weniger Spass, den Impfstoff ohne Gewinn verkaufen zu wollen.. Naja, die englische Regierung hat auch paralell auf andere Pferde gesetzt.
Merck, so viel es geht Gewinne daraus machen
Pfizer will einen angemessen Gewinn machen. Erkennt aber die Weltlage
Quelle
Protokolle Congress hearing gestern usa
link
https://investors.biontech.de/de/news-releases/...inbarung-mit-der-us
July 22 (Reuters) - The United States government said on Wednesday it will pay $1.95 billion for Pfizer Inc to produce and deliver 100 million doses of its COVID-19 vaccine candidate in the United States.
link:
https://www.cnbc.com/2020/07/22/...-doses-of-coronavirus-vaccine.html
Sicher nicht bevor die Restbestände bei Teegut im Resterampenregal vergammeln!
http://de.investing.com/analysis/...n-impfstoffbestellungen-200441469
9:47 AM ET 7/22/20 | Dow Jones
Related Quotes
9:40 AM ET 7/22/20
Symbol Last§% Chg
BNTX
97.17 6.08%§
PFE
38.10 3.86%§
Quotes delayed at least 15 minutes
By Josh Nathan-Kazis
The U.S. government has put in an order for enough doses of Pfizer and BioNTech experimental Covid-19 vaccine to inoculate nearly every American. It is paying a bit more than analysts expected.
Pfizer (ticker: PFE) and BioNTech (BNTX) said Wednesday that the companies are selling 100 million doses of the vaccine to the U.S. Department of Health and Human Services and the Department of Defense for $1.95 billion, a deal that prices each dose of the experimental vaccine at $19.50. The deal allows the U.S. government the option of buying an additional 500 million doses.
In a note on Tuesday morning, Mizuho analyst Vamil Divan called the price "somewhat higher than expected."
"We believe there have been a wide range of expectations for what Pfizer would ultimately charge, but believe overall it was closer to the $15 range per dose," Divan wrote.
Pfizer and BioNTech are testing the vaccine as a two-dose regimen, so 600 million doses would be enough to vaccinate almost the entire U.S. population of 320 million people. At the price the government is paying for the first 100 million doses, a full course would cost $39.
Americans would receive the vaccine free, according to the companies. Pfizer and BioNTech would provide the doses after the vaccine receives approval or emergency authorization from the Food and Drug Administration, and the government will make the payment after the first 100 million doses are delivered.
The price of Covid-19 vaccines is likely to become a key political issue in the coming months. On Tuesday, at a House subcommittee hearing, Rep. Jan Schakowsky, an Illinois Democrat, pressed drugmakers on whether they would price their Covid-19 vaccine at cost. Pfizer, along with Moderna (MRNA) and Merck (MRK), said they planned to seek a profit.
"We recognize these are extraordinary times, and our pricing will reflect that," Pfizer chief business officer John Young told Schakowsky. "During the term of the pandemic, we will price our potential vaccine consistent with the global health emergency we are facing."
The announcement of the deal with the U.S. government comes days after the companies announced a deal with the U.K. government to supply 30 million doses of the vaccine. The financial terms of that agreement weren't disclosed.
Shares of Pfizer jumped Wednesday, climbing 4.8% to $38.44 shortly after the market opened. Shares of BioNTech climbed 6.2% to $97.26. The S&P 500 was up 0.1%.
Pfizer and BioNTech have laid out among the most-aggressive timelines for developing their Covid-19 vaccine. The company has said it hopes to seek emergency-use authorization from the FDA in October.
While data remain preliminary, Raymond James analyst Steven Seedhouse wrote Monday that the Pfizer and BioNTech vaccine looked the most promising among the fastest-moving Covid-19 vaccine programs, compared with offerings by Moderna and AstraZeneca (AZN).
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
> Dow Jones Newswires
link
https://invezz.com/news/2020/07/22/...s-deal-with-the-u-s-government/
Analysten hatten mit 15 $ je Dosis gerechnet, es wurden aber fast 20 $, die "genaue Marge" wird nicht im Web stehen.
Vor dem Senat sprach man von angemessener Höhe..
:)
Das W im chart schließt sich langsam.
Schönen Abend
Weiterhin :
"Gerade gelesen, dass am Abend US-Präsident Trump ein Dekret zur Senkung der US-Medikamentenpreise unterzeichnen will. Deshalb stürzen alle Pharmawerte ab. Schaut mal nach, pfizer, novartis ...usw."....
..... aber keine infos / Quellen dazu bisher gefunden
link:
https://www.tickerreport.com/banking-finance/...-options-nysepfe.html
Keith Speights, Motley Fool beitragender Investmentanalyst | 24. Juli 2020 |
More on: ABBV BMY PFE
link:
https://www.fool.de/2020/07/24/...tien-sind-derzeit-noch-spottbillig/
link:
https://nationalpost.com/news/canada/...zer-biontech-covid-19-vaccine